Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue
Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.
You may also be interested in...
First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in launch market Japan looks set to be limited.
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.
Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML, analysts say.